Ramlacs的个人主页 - 老虎社区

Ramlacs

Ramlacs

暂无个人介绍

IP属地：未知

5关注

1粉丝

0主题

0勋章

2021-12-23

Good,,,thanks

This 2021 Loser Stock Could Be 2022's Biggest Winner

2021-12-23

Good!!!

This 2021 Loser Stock Could Be 2022's Biggest Winner

2021-12-22

Hold!!

Is Rivian Stock A Buy, Sell, Or Hold?

2021-10-22

Good sign to buy more,,, bullish

抱歉，原内容已删除

2021-10-20

Very good,,,more IPO’s and more choices

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4095866673656650","uuid":"4095866673656650","gmtCreate":1632787453481,"gmtModify":1632966893758,"name":"Ramlacs","pinyin":"ramlacs","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":5,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.06","exceedPercentage":"93.12%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.04","exceedPercentage":"60.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691750322,"gmtCreate":1640248851878,"gmtModify":1640248851978,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095866673656650","authorIdStr":"4095866673656650"},"themes":[],"htmlText":"Good,,,thanks&nbsp;","listText":"Good,,,thanks&nbsp;","text":"Good,,,thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691750322","repostId":"2193519088","repostType":2,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691727717,"gmtCreate":1640248829970,"gmtModify":1640248829970,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095866673656650","authorIdStr":"4095866673656650"},"themes":[],"htmlText":"Good!!!","listText":"Good!!!","text":"Good!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691727717","repostId":"2193519088","repostType":2,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":788,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691175154,"gmtCreate":1640156516203,"gmtModify":1640156516203,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095866673656650","authorIdStr":"4095866673656650"},"themes":[],"htmlText":"Hold!!","listText":"Hold!!","text":"Hold!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691175154","repostId":"1123940793","repostType":2,"repost":{"id":"1123940793","pubTimestamp":1640153635,"share":"https://www.laohu8.com/m/news/1123940793?lang=&edition=full","pubTime":"2021-12-22 14:13","market":"us","language":"en","title":"Is Rivian Stock A Buy, Sell, Or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=1123940793","media":"Seeking Alpha","summary":"Summary\n\nRivian stock has dropped more than 25% since our last Neutral call.\nThe company reported a ","content":"<p><b>Summary</b></p>\n<ul>\n <li>Rivian stock has dropped more than 25% since our last Neutral call.</li>\n <li>The company reported a slight production target miss in its FQ3 earnings call. However, we don't think investors should be overly worried.</li>\n <li>We discuss why we think RIVN stock is a Buy now.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69bdd77748b1c27c695aff2846bb30c6\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>Michael M. Santiago/Getty Images News</span></p>\n<p><b>Investment Thesis</b></p>\n<p>Rivian Automotive, Inc. (RIVN) recently released its first earnings reports for FQ3'21 as a public company. Notably, the company missed its 1,200 vehicle production target by \"a few hundred vehicles.\" However, we weren't surprised, given the current supply chain bottlenecks and the challenges in ramping production. Moreover, we don't think investors should be unduly concerned about its short-term production goal. Management was clear as it emphasized that its long-term production targets remain unaffected.</p>\n<p>Nevertheless, we believe that ramping production successfully will continue to be a key hurdle facing CEO RJ Scaringe &amp; Co. Investors sent the stock tumbling after its earnings report, which we believe the market took the opportunity to pare down risk. After all, RIVN stock had traded at an incredible market cap of $112.8B&nbsp;when we wrote our previous article. Following the recent sell-off, Rivian's market cap has dropped to $88B. Therefore, we believe it's an appropriate time to revisit our thesis on RIVN stock post-FQ3 earnings.</p>\n<p>We also discuss why we think the stock seems fairly valued now.</p>\n<p><b>Rivian Market Cap Trend</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a528b02874c529215e0428c40adc5ad1\" tg-width=\"640\" tg-height=\"331\" referrerpolicy=\"no-referrer\"><span>RIVN market cap analysis (as of 17 December'21).</span></p>\n<p>Readers can quickly glean that Rivian's market cap has dropped dramatically back to where it started life as a public company. It last registered a market cap of $88B, while it began trading with a market cap of $83.6B in early November.</p>\n<p>Nevertheless, Rivian's market cap still exceeded Ford (F) and General Motors (GM) market cap even as it just started making deliveries in September. Some investors find it incredulous that a company that hasn't even ramped production could be worth more than both the US auto leaders.</p>\n<p><b>Why We Think Rivian Investors Remain Optimistic Post-FQ3</b></p>\n<p>Rivian's report card wasn't a disaster, even if the company missed its production guidance for 2021. CEO RJ Scaringe offered assurances as he emphasized (edited):</p>\n<blockquote>\n For 2021, \n <i>we expect to produce a few hundred vehicles short of our initial 1,200 vehicle production target</i>. We do not believe any of our supply chain challenges represent long-term systemic issues. We remain well-positioned to capture and drive the accelerated large-scale adoption of sustainable transportation. However, a small number of suppliers or small number of components may be ramping a little slower, creating constraints or bottlenecks. Those challenges have been really a focal point for us over the last two and a half, three months. \n <i>But, these issues are short-term in nature and they are solvable problems</i>. So, we don't see any long-term systemic challenges associated with ramping the supply chain. (Rivian's FQ3'21 earnings call)\n</blockquote>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/36ec61d947f0a1da5f4d5883a8941a7d\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Rivian planned production capacity and delivery consensus estimates. Data source: S&amp;P Capital IQ, Barron's</span></p>\n<p>Rivian telegraphed that it would be commencing its new Georgia production facility in mid'22 and ready to begin production from 2024. Georgia's planned annual run rate is estimated at 400K. Therefore, it would afford Rivian a collective annual production capacity of 600K if we include its Illinois facility. Nevertheless, the company did not specify how long it would take to ramp production to its planned capacity. However, consensus estimates point to a relatively positive ramp through FY25. As a result, Rivian is estimated to deliver about 40K of vehicles in FY22. However, it would reach the 360K milestone by FY25, registering an estimated delivery CAGR of 108%. Its 360K estimate includes the 100K EDV orders from its exclusive last-mile delivery partner and cornerstone investor Amazon (AMZN).</p>\n<p>There's little doubt that the delivery cadence estimates look very aggressive. But, if done well, it's also not impossible. Keen investors should recall that Tesla (TSLA) took just two years to ramp Giga Shanghai from zero to its current 600K annual run rate. It has even recently made new investments to enhance its production capacity further. Rivian also seems highly confident that they can ramp successfully, as CEO RJ Scaringe emphasized (edited):</p>\n<blockquote>\n We've architected the product development to be capable of running more than one program and launching more than one program at once, but also to have those fast feedback loops between the different programs. So with that, the commercial van has actually learned a lot from the R1 platform and the R1 platform launch. What you see in terms of the facility in Georgia, is key for us from an expansion point of view. We're quite confident in the path ahead. All three of our vehicles have been certified for sale and they're being produced on two different production lines. \n <i>The organization was architected to facilitate running and operating multiple programs at the same time</i>. And so as we now look at what the ramp will look like for both R1T and R1S into next year, it really positions us to rapidly grow through the course of 2022. (Rivian's FQ3'21 earnings call)\n</blockquote>\n<p>While it's still early, Rivian investors are undoubtedly confident that the company can deliver on its production cadence to meet its delivery milestones. The company is not facing a demand issue compared to short-term supply constraints. They updated that R1 orders have climbed to 71K from 55K in the previous update. Nevertheless, these are cancelable orders, as their delivery timeline has been stretched to 2023 if a new order is placed now. Given that auto leaders General Motors, Ford, and Tesla will also be expected to compete with their pickup trucks soon, Rivian must maintain its production cadence. Therefore, we encourage investors to monitor their production milestones very carefully moving ahead.</p>\n<p><b>Investors Must Carefully Monitor Amazon's EDV Range</b></p>\n<p>The partnership with Amazon is critical to jumpstarting Rivian's ambitions into the commercial fleet segment. Not only does it offer the opportunity of massive fleet sales, but it also sells its fleet management subscriptions as part of its commercial sales. Consequently, it introduces a recurring software revenue stream component on top of its hardware revenue. It also applies to the Amazon fleet, as Rivian accentuated: \"That software subscription goes live basically now on the commercial side.\"</p>\n<p>Rivian is expected to deliver 10K EDV by 2022 following \"months of testing&nbsp;in 15 cities.\" Investors should remember that Amazon retains the right to change its number of orders. Therefore it's critical that Rivian can meet Amazon's expectations. We believe it has also driven Rivian to ramp production quickly. Given how quickly they secured their second production facility, we believe that the company seems confident in meeting its production targets, and consequently, Amazon's orders.</p>\n<p>Rivian emphasized that its EDV is capable of 201 miles range, and it is on track to deliver its vehicles to Amazon. However, a previous report by The Information highlighted some challenges in Amazon's testing, on top of its battery draining problem. The Information reported (edited):</p>\n<blockquote>\n Rivian said the Amazon vans would have a range of between 120 miles and 150 miles depending on their size. But one driver involved in testing the vans said the range could be much less, depending on the weather. The driver who spoke to The Information said the battery drained about 40% faster than normal if the van’s heating or cooling was on. As a result, drivers have been testing the vans on what they dubbed “nursery routes,” where vans didn’t venture too far away from the contractors’ headquarters. (The Information)\n</blockquote>\n<p>Nevertheless, Amazon's director of Global Fleets and Products, Ross Rachey, noted that once the vans are in production, \"they would have a range of 150 miles, which is double the range of the majority of Amazon's routes.\" Notably, the company also quickly emphasized that these test vans are not fully developed yet.</p>\n<p>We believe a successful launch program with Amazon could open up many potential opportunities outside of the Last Mile segment. Investors should note that Amazon's exclusive partnership with Rivian is limited to Last Mile. But, the commercial space is much larger than the Last Mile segment. Rivian also raved about its market opportunities in the larger commercial space, as Scaringe added (edited):</p>\n<blockquote>\n <i>Amazon represents such a large pool of demand for us.</i>So it's really critical that we do not starve them of vehicles. Nevertheless, the RCV platform was architected and designed \n <i>fully contemplating vehicles beyond Last Mile, such as in the cargo space</i>, or in the workspace. So there's a whole host of opportunities that exists both in large volumes, but also across a very long spread-out tail of commercial applications. Thus, we also have an eye on launching non-EDV versions on the RCV platform to capitalize on these opportunities. (Rivian's FQ3'21 earnings call)\n</blockquote>\n<p><b>So, is RIVN Stock a Buy/Hold/Sell Now?</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/264dc3dc91fc844d920e73a7f69cf920\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\"><span>Rivian revenue and adjusted EBIT margins mean consensus estimates. Data source: S&amp;P Capital IQ</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1069e7fc16920da396615f6df6ff5951\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>RIVN and TSLA stock EV/Fwd Revenue valuation comps. Data source: S&amp;P Capital IQ</span></p>\n<p>Consensus estimates point to a largely successful ramp, as we explained earlier. As a result, Rivian's revenue is estimated to reach $27.84B by FY25. However, the company is not expected to be profitable based on adjusted EBIT margins by then. Therefore, investors are encouraged to monitor its production ramp and profitability dynamics moving forward carefully.</p>\n<p>Nevertheless, its valuations have dropped significantly since its earlier momentum spike. The stock has declined more than 25% since our Neutral call, as we encouraged investors to wait for the dip.</p>\n<p>If we consider Rivian's valuations against Tesla moving forward, it may seem more reasonable than the EV leader. However, investors should note that Tesla is already a solidly profitable EV maker. It also has proven its production ramp capabilities exceptionally well. Moreover, its brand value has also increased tremendously globally. Therefore, comparing their revenue multiples directly without adjusting for Tesla's advantages would not make sense.</p>\n<p>Based on Rivian stock's EV/FY25 revenue multiple of 3.4x, it's trading at 50% of Tesla's FY25 revenue multiple. Therefore, we think RIVN stock looks fairly valued now. Nevertheless, we believe that RIVN stock remains a highly speculative play. However, the company seems to be getting well on track to meet its mid-term production guidance. Therefore, the current weakness could offer speculative investors a potential opportunity to add exposure at a more reasonable valuation.</p>\n<p>Consequently,<i>we revise our rating on RIVN stock to Buy.</i>However, we would like to caution that RIVN stock may be suitable for speculative investors only. Moreover, the stock could continue to exhibit tremendous volatility. Therefore, investors are encouraged to add in phases.</p>\n<p>This article was written by&nbsp;JR Research.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Rivian Stock A Buy, Sell, Or Hold?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Rivian Stock A Buy, Sell, Or Hold?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 14:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4476199-rivian-stock-buy-sell-hold><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nRivian stock has dropped more than 25% since our last Neutral call.\nThe company reported a slight production target miss in its FQ3 earnings call. However, we don't think investors should be ...</p>\n\n<a href=\"https://seekingalpha.com/article/4476199-rivian-stock-buy-sell-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"source_url":"https://seekingalpha.com/article/4476199-rivian-stock-buy-sell-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123940793","content_text":"Summary\n\nRivian stock has dropped more than 25% since our last Neutral call.\nThe company reported a slight production target miss in its FQ3 earnings call. However, we don't think investors should be overly worried.\nWe discuss why we think RIVN stock is a Buy now.\n\nMichael M. Santiago/Getty Images News\nInvestment Thesis\nRivian Automotive, Inc. (RIVN) recently released its first earnings reports for FQ3'21 as a public company. Notably, the company missed its 1,200 vehicle production target by \"a few hundred vehicles.\" However, we weren't surprised, given the current supply chain bottlenecks and the challenges in ramping production. Moreover, we don't think investors should be unduly concerned about its short-term production goal. Management was clear as it emphasized that its long-term production targets remain unaffected.\nNevertheless, we believe that ramping production successfully will continue to be a key hurdle facing CEO RJ Scaringe & Co. Investors sent the stock tumbling after its earnings report, which we believe the market took the opportunity to pare down risk. After all, RIVN stock had traded at an incredible market cap of $112.8B when we wrote our previous article. Following the recent sell-off, Rivian's market cap has dropped to $88B. Therefore, we believe it's an appropriate time to revisit our thesis on RIVN stock post-FQ3 earnings.\nWe also discuss why we think the stock seems fairly valued now.\nRivian Market Cap Trend\nRIVN market cap analysis (as of 17 December'21).\nReaders can quickly glean that Rivian's market cap has dropped dramatically back to where it started life as a public company. It last registered a market cap of $88B, while it began trading with a market cap of $83.6B in early November.\nNevertheless, Rivian's market cap still exceeded Ford (F) and General Motors (GM) market cap even as it just started making deliveries in September. Some investors find it incredulous that a company that hasn't even ramped production could be worth more than both the US auto leaders.\nWhy We Think Rivian Investors Remain Optimistic Post-FQ3\nRivian's report card wasn't a disaster, even if the company missed its production guidance for 2021. CEO RJ Scaringe offered assurances as he emphasized (edited):\n\n For 2021, \n we expect to produce a few hundred vehicles short of our initial 1,200 vehicle production target. We do not believe any of our supply chain challenges represent long-term systemic issues. We remain well-positioned to capture and drive the accelerated large-scale adoption of sustainable transportation. However, a small number of suppliers or small number of components may be ramping a little slower, creating constraints or bottlenecks. Those challenges have been really a focal point for us over the last two and a half, three months. \n But, these issues are short-term in nature and they are solvable problems. So, we don't see any long-term systemic challenges associated with ramping the supply chain. (Rivian's FQ3'21 earnings call)\n\nRivian planned production capacity and delivery consensus estimates. Data source: S&P Capital IQ, Barron's\nRivian telegraphed that it would be commencing its new Georgia production facility in mid'22 and ready to begin production from 2024. Georgia's planned annual run rate is estimated at 400K. Therefore, it would afford Rivian a collective annual production capacity of 600K if we include its Illinois facility. Nevertheless, the company did not specify how long it would take to ramp production to its planned capacity. However, consensus estimates point to a relatively positive ramp through FY25. As a result, Rivian is estimated to deliver about 40K of vehicles in FY22. However, it would reach the 360K milestone by FY25, registering an estimated delivery CAGR of 108%. Its 360K estimate includes the 100K EDV orders from its exclusive last-mile delivery partner and cornerstone investor Amazon (AMZN).\nThere's little doubt that the delivery cadence estimates look very aggressive. But, if done well, it's also not impossible. Keen investors should recall that Tesla (TSLA) took just two years to ramp Giga Shanghai from zero to its current 600K annual run rate. It has even recently made new investments to enhance its production capacity further. Rivian also seems highly confident that they can ramp successfully, as CEO RJ Scaringe emphasized (edited):\n\n We've architected the product development to be capable of running more than one program and launching more than one program at once, but also to have those fast feedback loops between the different programs. So with that, the commercial van has actually learned a lot from the R1 platform and the R1 platform launch. What you see in terms of the facility in Georgia, is key for us from an expansion point of view. We're quite confident in the path ahead. All three of our vehicles have been certified for sale and they're being produced on two different production lines. \n The organization was architected to facilitate running and operating multiple programs at the same time. And so as we now look at what the ramp will look like for both R1T and R1S into next year, it really positions us to rapidly grow through the course of 2022. (Rivian's FQ3'21 earnings call)\n\nWhile it's still early, Rivian investors are undoubtedly confident that the company can deliver on its production cadence to meet its delivery milestones. The company is not facing a demand issue compared to short-term supply constraints. They updated that R1 orders have climbed to 71K from 55K in the previous update. Nevertheless, these are cancelable orders, as their delivery timeline has been stretched to 2023 if a new order is placed now. Given that auto leaders General Motors, Ford, and Tesla will also be expected to compete with their pickup trucks soon, Rivian must maintain its production cadence. Therefore, we encourage investors to monitor their production milestones very carefully moving ahead.\nInvestors Must Carefully Monitor Amazon's EDV Range\nThe partnership with Amazon is critical to jumpstarting Rivian's ambitions into the commercial fleet segment. Not only does it offer the opportunity of massive fleet sales, but it also sells its fleet management subscriptions as part of its commercial sales. Consequently, it introduces a recurring software revenue stream component on top of its hardware revenue. It also applies to the Amazon fleet, as Rivian accentuated: \"That software subscription goes live basically now on the commercial side.\"\nRivian is expected to deliver 10K EDV by 2022 following \"months of testing in 15 cities.\" Investors should remember that Amazon retains the right to change its number of orders. Therefore it's critical that Rivian can meet Amazon's expectations. We believe it has also driven Rivian to ramp production quickly. Given how quickly they secured their second production facility, we believe that the company seems confident in meeting its production targets, and consequently, Amazon's orders.\nRivian emphasized that its EDV is capable of 201 miles range, and it is on track to deliver its vehicles to Amazon. However, a previous report by The Information highlighted some challenges in Amazon's testing, on top of its battery draining problem. The Information reported (edited):\n\n Rivian said the Amazon vans would have a range of between 120 miles and 150 miles depending on their size. But one driver involved in testing the vans said the range could be much less, depending on the weather. The driver who spoke to The Information said the battery drained about 40% faster than normal if the van’s heating or cooling was on. As a result, drivers have been testing the vans on what they dubbed “nursery routes,” where vans didn’t venture too far away from the contractors’ headquarters. (The Information)\n\nNevertheless, Amazon's director of Global Fleets and Products, Ross Rachey, noted that once the vans are in production, \"they would have a range of 150 miles, which is double the range of the majority of Amazon's routes.\" Notably, the company also quickly emphasized that these test vans are not fully developed yet.\nWe believe a successful launch program with Amazon could open up many potential opportunities outside of the Last Mile segment. Investors should note that Amazon's exclusive partnership with Rivian is limited to Last Mile. But, the commercial space is much larger than the Last Mile segment. Rivian also raved about its market opportunities in the larger commercial space, as Scaringe added (edited):\n\nAmazon represents such a large pool of demand for us.So it's really critical that we do not starve them of vehicles. Nevertheless, the RCV platform was architected and designed \n fully contemplating vehicles beyond Last Mile, such as in the cargo space, or in the workspace. So there's a whole host of opportunities that exists both in large volumes, but also across a very long spread-out tail of commercial applications. Thus, we also have an eye on launching non-EDV versions on the RCV platform to capitalize on these opportunities. (Rivian's FQ3'21 earnings call)\n\nSo, is RIVN Stock a Buy/Hold/Sell Now?\nRivian revenue and adjusted EBIT margins mean consensus estimates. Data source: S&P Capital IQ\nRIVN and TSLA stock EV/Fwd Revenue valuation comps. Data source: S&P Capital IQ\nConsensus estimates point to a largely successful ramp, as we explained earlier. As a result, Rivian's revenue is estimated to reach $27.84B by FY25. However, the company is not expected to be profitable based on adjusted EBIT margins by then. Therefore, investors are encouraged to monitor its production ramp and profitability dynamics moving forward carefully.\nNevertheless, its valuations have dropped significantly since its earlier momentum spike. The stock has declined more than 25% since our Neutral call, as we encouraged investors to wait for the dip.\nIf we consider Rivian's valuations against Tesla moving forward, it may seem more reasonable than the EV leader. However, investors should note that Tesla is already a solidly profitable EV maker. It also has proven its production ramp capabilities exceptionally well. Moreover, its brand value has also increased tremendously globally. Therefore, comparing their revenue multiples directly without adjusting for Tesla's advantages would not make sense.\nBased on Rivian stock's EV/FY25 revenue multiple of 3.4x, it's trading at 50% of Tesla's FY25 revenue multiple. Therefore, we think RIVN stock looks fairly valued now. Nevertheless, we believe that RIVN stock remains a highly speculative play. However, the company seems to be getting well on track to meet its mid-term production guidance. Therefore, the current weakness could offer speculative investors a potential opportunity to add exposure at a more reasonable valuation.\nConsequently,we revise our rating on RIVN stock to Buy.However, we would like to caution that RIVN stock may be suitable for speculative investors only. Moreover, the stock could continue to exhibit tremendous volatility. Therefore, investors are encouraged to add in phases.\nThis article was written by JR Research.","news_type":1},"isVote":1,"tweetType":1,"viewCount":873,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853782666,"gmtCreate":1634842198250,"gmtModify":1634842198360,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095866673656650","authorIdStr":"4095866673656650"},"themes":[],"htmlText":"Good sign to buy more,,, bullish","listText":"Good sign to buy more,,, bullish","text":"Good sign to buy more,,, bullish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853782666","repostId":"2177426435","repostType":2,"isVote":1,"tweetType":1,"viewCount":723,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859195823,"gmtCreate":1634664025864,"gmtModify":1634664025991,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095866673656650","authorIdStr":"4095866673656650"},"themes":[],"htmlText":"Very good,,,more IPO’s and more choices","listText":"Very good,,,more IPO’s and more choices","text":"Very good,,,more IPO’s and more choices","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859195823","repostId":"1155284413","repostType":2,"isVote":1,"tweetType":1,"viewCount":797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":691175154,"gmtCreate":1640156516203,"gmtModify":1640156516203,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095866673656650","authorIdStr":"4095866673656650"},"themes":[],"htmlText":"Hold!!","listText":"Hold!!","text":"Hold!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691175154","repostId":"1123940793","repostType":2,"repost":{"id":"1123940793","pubTimestamp":1640153635,"share":"https://www.laohu8.com/m/news/1123940793?lang=&edition=full","pubTime":"2021-12-22 14:13","market":"us","language":"en","title":"Is Rivian Stock A Buy, Sell, Or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=1123940793","media":"Seeking Alpha","summary":"Summary\n\nRivian stock has dropped more than 25% since our last Neutral call.\nThe company reported a ","content":"<p><b>Summary</b></p>\n<ul>\n <li>Rivian stock has dropped more than 25% since our last Neutral call.</li>\n <li>The company reported a slight production target miss in its FQ3 earnings call. However, we don't think investors should be overly worried.</li>\n <li>We discuss why we think RIVN stock is a Buy now.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69bdd77748b1c27c695aff2846bb30c6\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>Michael M. Santiago/Getty Images News</span></p>\n<p><b>Investment Thesis</b></p>\n<p>Rivian Automotive, Inc. (RIVN) recently released its first earnings reports for FQ3'21 as a public company. Notably, the company missed its 1,200 vehicle production target by \"a few hundred vehicles.\" However, we weren't surprised, given the current supply chain bottlenecks and the challenges in ramping production. Moreover, we don't think investors should be unduly concerned about its short-term production goal. Management was clear as it emphasized that its long-term production targets remain unaffected.</p>\n<p>Nevertheless, we believe that ramping production successfully will continue to be a key hurdle facing CEO RJ Scaringe &amp; Co. Investors sent the stock tumbling after its earnings report, which we believe the market took the opportunity to pare down risk. After all, RIVN stock had traded at an incredible market cap of $112.8B&nbsp;when we wrote our previous article. Following the recent sell-off, Rivian's market cap has dropped to $88B. Therefore, we believe it's an appropriate time to revisit our thesis on RIVN stock post-FQ3 earnings.</p>\n<p>We also discuss why we think the stock seems fairly valued now.</p>\n<p><b>Rivian Market Cap Trend</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a528b02874c529215e0428c40adc5ad1\" tg-width=\"640\" tg-height=\"331\" referrerpolicy=\"no-referrer\"><span>RIVN market cap analysis (as of 17 December'21).</span></p>\n<p>Readers can quickly glean that Rivian's market cap has dropped dramatically back to where it started life as a public company. It last registered a market cap of $88B, while it began trading with a market cap of $83.6B in early November.</p>\n<p>Nevertheless, Rivian's market cap still exceeded Ford (F) and General Motors (GM) market cap even as it just started making deliveries in September. Some investors find it incredulous that a company that hasn't even ramped production could be worth more than both the US auto leaders.</p>\n<p><b>Why We Think Rivian Investors Remain Optimistic Post-FQ3</b></p>\n<p>Rivian's report card wasn't a disaster, even if the company missed its production guidance for 2021. CEO RJ Scaringe offered assurances as he emphasized (edited):</p>\n<blockquote>\n For 2021, \n <i>we expect to produce a few hundred vehicles short of our initial 1,200 vehicle production target</i>. We do not believe any of our supply chain challenges represent long-term systemic issues. We remain well-positioned to capture and drive the accelerated large-scale adoption of sustainable transportation. However, a small number of suppliers or small number of components may be ramping a little slower, creating constraints or bottlenecks. Those challenges have been really a focal point for us over the last two and a half, three months. \n <i>But, these issues are short-term in nature and they are solvable problems</i>. So, we don't see any long-term systemic challenges associated with ramping the supply chain. (Rivian's FQ3'21 earnings call)\n</blockquote>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/36ec61d947f0a1da5f4d5883a8941a7d\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Rivian planned production capacity and delivery consensus estimates. Data source: S&amp;P Capital IQ, Barron's</span></p>\n<p>Rivian telegraphed that it would be commencing its new Georgia production facility in mid'22 and ready to begin production from 2024. Georgia's planned annual run rate is estimated at 400K. Therefore, it would afford Rivian a collective annual production capacity of 600K if we include its Illinois facility. Nevertheless, the company did not specify how long it would take to ramp production to its planned capacity. However, consensus estimates point to a relatively positive ramp through FY25. As a result, Rivian is estimated to deliver about 40K of vehicles in FY22. However, it would reach the 360K milestone by FY25, registering an estimated delivery CAGR of 108%. Its 360K estimate includes the 100K EDV orders from its exclusive last-mile delivery partner and cornerstone investor Amazon (AMZN).</p>\n<p>There's little doubt that the delivery cadence estimates look very aggressive. But, if done well, it's also not impossible. Keen investors should recall that Tesla (TSLA) took just two years to ramp Giga Shanghai from zero to its current 600K annual run rate. It has even recently made new investments to enhance its production capacity further. Rivian also seems highly confident that they can ramp successfully, as CEO RJ Scaringe emphasized (edited):</p>\n<blockquote>\n We've architected the product development to be capable of running more than one program and launching more than one program at once, but also to have those fast feedback loops between the different programs. So with that, the commercial van has actually learned a lot from the R1 platform and the R1 platform launch. What you see in terms of the facility in Georgia, is key for us from an expansion point of view. We're quite confident in the path ahead. All three of our vehicles have been certified for sale and they're being produced on two different production lines. \n <i>The organization was architected to facilitate running and operating multiple programs at the same time</i>. And so as we now look at what the ramp will look like for both R1T and R1S into next year, it really positions us to rapidly grow through the course of 2022. (Rivian's FQ3'21 earnings call)\n</blockquote>\n<p>While it's still early, Rivian investors are undoubtedly confident that the company can deliver on its production cadence to meet its delivery milestones. The company is not facing a demand issue compared to short-term supply constraints. They updated that R1 orders have climbed to 71K from 55K in the previous update. Nevertheless, these are cancelable orders, as their delivery timeline has been stretched to 2023 if a new order is placed now. Given that auto leaders General Motors, Ford, and Tesla will also be expected to compete with their pickup trucks soon, Rivian must maintain its production cadence. Therefore, we encourage investors to monitor their production milestones very carefully moving ahead.</p>\n<p><b>Investors Must Carefully Monitor Amazon's EDV Range</b></p>\n<p>The partnership with Amazon is critical to jumpstarting Rivian's ambitions into the commercial fleet segment. Not only does it offer the opportunity of massive fleet sales, but it also sells its fleet management subscriptions as part of its commercial sales. Consequently, it introduces a recurring software revenue stream component on top of its hardware revenue. It also applies to the Amazon fleet, as Rivian accentuated: \"That software subscription goes live basically now on the commercial side.\"</p>\n<p>Rivian is expected to deliver 10K EDV by 2022 following \"months of testing&nbsp;in 15 cities.\" Investors should remember that Amazon retains the right to change its number of orders. Therefore it's critical that Rivian can meet Amazon's expectations. We believe it has also driven Rivian to ramp production quickly. Given how quickly they secured their second production facility, we believe that the company seems confident in meeting its production targets, and consequently, Amazon's orders.</p>\n<p>Rivian emphasized that its EDV is capable of 201 miles range, and it is on track to deliver its vehicles to Amazon. However, a previous report by The Information highlighted some challenges in Amazon's testing, on top of its battery draining problem. The Information reported (edited):</p>\n<blockquote>\n Rivian said the Amazon vans would have a range of between 120 miles and 150 miles depending on their size. But one driver involved in testing the vans said the range could be much less, depending on the weather. The driver who spoke to The Information said the battery drained about 40% faster than normal if the van’s heating or cooling was on. As a result, drivers have been testing the vans on what they dubbed “nursery routes,” where vans didn’t venture too far away from the contractors’ headquarters. (The Information)\n</blockquote>\n<p>Nevertheless, Amazon's director of Global Fleets and Products, Ross Rachey, noted that once the vans are in production, \"they would have a range of 150 miles, which is double the range of the majority of Amazon's routes.\" Notably, the company also quickly emphasized that these test vans are not fully developed yet.</p>\n<p>We believe a successful launch program with Amazon could open up many potential opportunities outside of the Last Mile segment. Investors should note that Amazon's exclusive partnership with Rivian is limited to Last Mile. But, the commercial space is much larger than the Last Mile segment. Rivian also raved about its market opportunities in the larger commercial space, as Scaringe added (edited):</p>\n<blockquote>\n <i>Amazon represents such a large pool of demand for us.</i>So it's really critical that we do not starve them of vehicles. Nevertheless, the RCV platform was architected and designed \n <i>fully contemplating vehicles beyond Last Mile, such as in the cargo space</i>, or in the workspace. So there's a whole host of opportunities that exists both in large volumes, but also across a very long spread-out tail of commercial applications. Thus, we also have an eye on launching non-EDV versions on the RCV platform to capitalize on these opportunities. (Rivian's FQ3'21 earnings call)\n</blockquote>\n<p><b>So, is RIVN Stock a Buy/Hold/Sell Now?</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/264dc3dc91fc844d920e73a7f69cf920\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\"><span>Rivian revenue and adjusted EBIT margins mean consensus estimates. Data source: S&amp;P Capital IQ</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1069e7fc16920da396615f6df6ff5951\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>RIVN and TSLA stock EV/Fwd Revenue valuation comps. Data source: S&amp;P Capital IQ</span></p>\n<p>Consensus estimates point to a largely successful ramp, as we explained earlier. As a result, Rivian's revenue is estimated to reach $27.84B by FY25. However, the company is not expected to be profitable based on adjusted EBIT margins by then. Therefore, investors are encouraged to monitor its production ramp and profitability dynamics moving forward carefully.</p>\n<p>Nevertheless, its valuations have dropped significantly since its earlier momentum spike. The stock has declined more than 25% since our Neutral call, as we encouraged investors to wait for the dip.</p>\n<p>If we consider Rivian's valuations against Tesla moving forward, it may seem more reasonable than the EV leader. However, investors should note that Tesla is already a solidly profitable EV maker. It also has proven its production ramp capabilities exceptionally well. Moreover, its brand value has also increased tremendously globally. Therefore, comparing their revenue multiples directly without adjusting for Tesla's advantages would not make sense.</p>\n<p>Based on Rivian stock's EV/FY25 revenue multiple of 3.4x, it's trading at 50% of Tesla's FY25 revenue multiple. Therefore, we think RIVN stock looks fairly valued now. Nevertheless, we believe that RIVN stock remains a highly speculative play. However, the company seems to be getting well on track to meet its mid-term production guidance. Therefore, the current weakness could offer speculative investors a potential opportunity to add exposure at a more reasonable valuation.</p>\n<p>Consequently,<i>we revise our rating on RIVN stock to Buy.</i>However, we would like to caution that RIVN stock may be suitable for speculative investors only. Moreover, the stock could continue to exhibit tremendous volatility. Therefore, investors are encouraged to add in phases.</p>\n<p>This article was written by&nbsp;JR Research.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Rivian Stock A Buy, Sell, Or Hold?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Rivian Stock A Buy, Sell, Or Hold?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 14:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4476199-rivian-stock-buy-sell-hold><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nRivian stock has dropped more than 25% since our last Neutral call.\nThe company reported a slight production target miss in its FQ3 earnings call. However, we don't think investors should be ...</p>\n\n<a href=\"https://seekingalpha.com/article/4476199-rivian-stock-buy-sell-hold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"source_url":"https://seekingalpha.com/article/4476199-rivian-stock-buy-sell-hold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123940793","content_text":"Summary\n\nRivian stock has dropped more than 25% since our last Neutral call.\nThe company reported a slight production target miss in its FQ3 earnings call. However, we don't think investors should be overly worried.\nWe discuss why we think RIVN stock is a Buy now.\n\nMichael M. Santiago/Getty Images News\nInvestment Thesis\nRivian Automotive, Inc. (RIVN) recently released its first earnings reports for FQ3'21 as a public company. Notably, the company missed its 1,200 vehicle production target by \"a few hundred vehicles.\" However, we weren't surprised, given the current supply chain bottlenecks and the challenges in ramping production. Moreover, we don't think investors should be unduly concerned about its short-term production goal. Management was clear as it emphasized that its long-term production targets remain unaffected.\nNevertheless, we believe that ramping production successfully will continue to be a key hurdle facing CEO RJ Scaringe & Co. Investors sent the stock tumbling after its earnings report, which we believe the market took the opportunity to pare down risk. After all, RIVN stock had traded at an incredible market cap of $112.8B when we wrote our previous article. Following the recent sell-off, Rivian's market cap has dropped to $88B. Therefore, we believe it's an appropriate time to revisit our thesis on RIVN stock post-FQ3 earnings.\nWe also discuss why we think the stock seems fairly valued now.\nRivian Market Cap Trend\nRIVN market cap analysis (as of 17 December'21).\nReaders can quickly glean that Rivian's market cap has dropped dramatically back to where it started life as a public company. It last registered a market cap of $88B, while it began trading with a market cap of $83.6B in early November.\nNevertheless, Rivian's market cap still exceeded Ford (F) and General Motors (GM) market cap even as it just started making deliveries in September. Some investors find it incredulous that a company that hasn't even ramped production could be worth more than both the US auto leaders.\nWhy We Think Rivian Investors Remain Optimistic Post-FQ3\nRivian's report card wasn't a disaster, even if the company missed its production guidance for 2021. CEO RJ Scaringe offered assurances as he emphasized (edited):\n\n For 2021, \n we expect to produce a few hundred vehicles short of our initial 1,200 vehicle production target. We do not believe any of our supply chain challenges represent long-term systemic issues. We remain well-positioned to capture and drive the accelerated large-scale adoption of sustainable transportation. However, a small number of suppliers or small number of components may be ramping a little slower, creating constraints or bottlenecks. Those challenges have been really a focal point for us over the last two and a half, three months. \n But, these issues are short-term in nature and they are solvable problems. So, we don't see any long-term systemic challenges associated with ramping the supply chain. (Rivian's FQ3'21 earnings call)\n\nRivian planned production capacity and delivery consensus estimates. Data source: S&P Capital IQ, Barron's\nRivian telegraphed that it would be commencing its new Georgia production facility in mid'22 and ready to begin production from 2024. Georgia's planned annual run rate is estimated at 400K. Therefore, it would afford Rivian a collective annual production capacity of 600K if we include its Illinois facility. Nevertheless, the company did not specify how long it would take to ramp production to its planned capacity. However, consensus estimates point to a relatively positive ramp through FY25. As a result, Rivian is estimated to deliver about 40K of vehicles in FY22. However, it would reach the 360K milestone by FY25, registering an estimated delivery CAGR of 108%. Its 360K estimate includes the 100K EDV orders from its exclusive last-mile delivery partner and cornerstone investor Amazon (AMZN).\nThere's little doubt that the delivery cadence estimates look very aggressive. But, if done well, it's also not impossible. Keen investors should recall that Tesla (TSLA) took just two years to ramp Giga Shanghai from zero to its current 600K annual run rate. It has even recently made new investments to enhance its production capacity further. Rivian also seems highly confident that they can ramp successfully, as CEO RJ Scaringe emphasized (edited):\n\n We've architected the product development to be capable of running more than one program and launching more than one program at once, but also to have those fast feedback loops between the different programs. So with that, the commercial van has actually learned a lot from the R1 platform and the R1 platform launch. What you see in terms of the facility in Georgia, is key for us from an expansion point of view. We're quite confident in the path ahead. All three of our vehicles have been certified for sale and they're being produced on two different production lines. \n The organization was architected to facilitate running and operating multiple programs at the same time. And so as we now look at what the ramp will look like for both R1T and R1S into next year, it really positions us to rapidly grow through the course of 2022. (Rivian's FQ3'21 earnings call)\n\nWhile it's still early, Rivian investors are undoubtedly confident that the company can deliver on its production cadence to meet its delivery milestones. The company is not facing a demand issue compared to short-term supply constraints. They updated that R1 orders have climbed to 71K from 55K in the previous update. Nevertheless, these are cancelable orders, as their delivery timeline has been stretched to 2023 if a new order is placed now. Given that auto leaders General Motors, Ford, and Tesla will also be expected to compete with their pickup trucks soon, Rivian must maintain its production cadence. Therefore, we encourage investors to monitor their production milestones very carefully moving ahead.\nInvestors Must Carefully Monitor Amazon's EDV Range\nThe partnership with Amazon is critical to jumpstarting Rivian's ambitions into the commercial fleet segment. Not only does it offer the opportunity of massive fleet sales, but it also sells its fleet management subscriptions as part of its commercial sales. Consequently, it introduces a recurring software revenue stream component on top of its hardware revenue. It also applies to the Amazon fleet, as Rivian accentuated: \"That software subscription goes live basically now on the commercial side.\"\nRivian is expected to deliver 10K EDV by 2022 following \"months of testing in 15 cities.\" Investors should remember that Amazon retains the right to change its number of orders. Therefore it's critical that Rivian can meet Amazon's expectations. We believe it has also driven Rivian to ramp production quickly. Given how quickly they secured their second production facility, we believe that the company seems confident in meeting its production targets, and consequently, Amazon's orders.\nRivian emphasized that its EDV is capable of 201 miles range, and it is on track to deliver its vehicles to Amazon. However, a previous report by The Information highlighted some challenges in Amazon's testing, on top of its battery draining problem. The Information reported (edited):\n\n Rivian said the Amazon vans would have a range of between 120 miles and 150 miles depending on their size. But one driver involved in testing the vans said the range could be much less, depending on the weather. The driver who spoke to The Information said the battery drained about 40% faster than normal if the van’s heating or cooling was on. As a result, drivers have been testing the vans on what they dubbed “nursery routes,” where vans didn’t venture too far away from the contractors’ headquarters. (The Information)\n\nNevertheless, Amazon's director of Global Fleets and Products, Ross Rachey, noted that once the vans are in production, \"they would have a range of 150 miles, which is double the range of the majority of Amazon's routes.\" Notably, the company also quickly emphasized that these test vans are not fully developed yet.\nWe believe a successful launch program with Amazon could open up many potential opportunities outside of the Last Mile segment. Investors should note that Amazon's exclusive partnership with Rivian is limited to Last Mile. But, the commercial space is much larger than the Last Mile segment. Rivian also raved about its market opportunities in the larger commercial space, as Scaringe added (edited):\n\nAmazon represents such a large pool of demand for us.So it's really critical that we do not starve them of vehicles. Nevertheless, the RCV platform was architected and designed \n fully contemplating vehicles beyond Last Mile, such as in the cargo space, or in the workspace. So there's a whole host of opportunities that exists both in large volumes, but also across a very long spread-out tail of commercial applications. Thus, we also have an eye on launching non-EDV versions on the RCV platform to capitalize on these opportunities. (Rivian's FQ3'21 earnings call)\n\nSo, is RIVN Stock a Buy/Hold/Sell Now?\nRivian revenue and adjusted EBIT margins mean consensus estimates. Data source: S&P Capital IQ\nRIVN and TSLA stock EV/Fwd Revenue valuation comps. Data source: S&P Capital IQ\nConsensus estimates point to a largely successful ramp, as we explained earlier. As a result, Rivian's revenue is estimated to reach $27.84B by FY25. However, the company is not expected to be profitable based on adjusted EBIT margins by then. Therefore, investors are encouraged to monitor its production ramp and profitability dynamics moving forward carefully.\nNevertheless, its valuations have dropped significantly since its earlier momentum spike. The stock has declined more than 25% since our Neutral call, as we encouraged investors to wait for the dip.\nIf we consider Rivian's valuations against Tesla moving forward, it may seem more reasonable than the EV leader. However, investors should note that Tesla is already a solidly profitable EV maker. It also has proven its production ramp capabilities exceptionally well. Moreover, its brand value has also increased tremendously globally. Therefore, comparing their revenue multiples directly without adjusting for Tesla's advantages would not make sense.\nBased on Rivian stock's EV/FY25 revenue multiple of 3.4x, it's trading at 50% of Tesla's FY25 revenue multiple. Therefore, we think RIVN stock looks fairly valued now. Nevertheless, we believe that RIVN stock remains a highly speculative play. However, the company seems to be getting well on track to meet its mid-term production guidance. Therefore, the current weakness could offer speculative investors a potential opportunity to add exposure at a more reasonable valuation.\nConsequently,we revise our rating on RIVN stock to Buy.However, we would like to caution that RIVN stock may be suitable for speculative investors only. Moreover, the stock could continue to exhibit tremendous volatility. Therefore, investors are encouraged to add in phases.\nThis article was written by JR Research.","news_type":1},"isVote":1,"tweetType":1,"viewCount":873,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691750322,"gmtCreate":1640248851878,"gmtModify":1640248851978,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095866673656650","authorIdStr":"4095866673656650"},"themes":[],"htmlText":"Good,,,thanks&nbsp;","listText":"Good,,,thanks&nbsp;","text":"Good,,,thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691750322","repostId":"2193519088","repostType":2,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691727717,"gmtCreate":1640248829970,"gmtModify":1640248829970,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095866673656650","authorIdStr":"4095866673656650"},"themes":[],"htmlText":"Good!!!","listText":"Good!!!","text":"Good!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691727717","repostId":"2193519088","repostType":2,"repost":{"id":"2193519088","pubTimestamp":1640226997,"share":"https://www.laohu8.com/m/news/2193519088?lang=&edition=full","pubTime":"2021-12-23 10:36","market":"us","language":"en","title":"This 2021 Loser Stock Could Be 2022's Biggest Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2193519088","media":"Motley Fool","summary":"From 2020 hero to 2021 zero, Teladoc now may be a big winner in 2022.","content":"<p>Virtual healthcare company <b>Teladoc Health</b> (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.</p>\n<p>But let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:</p>\n<h2>Whole-person care is the new healthcare</h2>\n<p>The traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f362ef0d223dfdddfad2dc7d9316a096\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image Source: Getty Images.</span></p>\n<p>All of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"</p>\n<p>The concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.</p>\n<h2>A new reality?</h2>\n<p>Teladoc was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/680d2261d92893b1cb00307f63a567cc\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>TDOC Revenue (Quarterly YOY Growth) data by YCharts</span></p>\n<p>Revenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?</p>\n<p>Teladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.</p>\n<p>While we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.</p>\n<h2>Years of growth ahead</h2>\n<p>Teladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.</p>\n<p>In November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.</p>\n<p>The company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.</p>\n<h2>Depressed valuation could mean big gains ahead</h2>\n<p>Investors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.</p>\n<h2><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be352f0c1d5403e02a9a8061c34db1f5\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>TDOC PS Ratio data by YCharts</span></p></h2>\n<p>No doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.</p>\n<p>If the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.</p>\n<p>Teladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This 2021 Loser Stock Could Be 2022's Biggest Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis 2021 Loser Stock Could Be 2022's Biggest Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","TDOC":"Teladoc Health Inc.","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术","BK4534":"瑞士信贷持仓","BK4567":"ESG概念"},"source_url":"https://www.fool.com/investing/2021/12/22/this-2021-loser-stock-could-be-2022s-biggest-winne/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193519088","content_text":"Virtual healthcare company Teladoc Health (NYSE:TDOC) will be the 2022 darling of Wall Street. Ok, don't laugh; the stock is down roughly 66% from its highs earlier this year. I don't blame you for being skeptical of this stock, which has been a complete loser over the past year.\nBut let's consider a few things. The company spent 2021 evolving, moving closer to its long-term vision of what healthcare could become. Throw in a COVID-19 virus that doesn't want to disappear, and we could have fireworks in 2022. Let's dive deeper:\nWhole-person care is the new healthcare\nThe traditional healthcare system is very fragmented. Patients see an average of 19 doctors over their lifetime, and each new doctor often means a new practice, a new relationship with a care provider, and varying medical records.\nImage Source: Getty Images.\nAll of this can make the care we receive an inconsistent experience, leaving patients unsatisfied and health ailments unresolved, potentially causing more harm. Teladoc has spent years acquiring and developing the assets to build Primary360, the front door to what it calls \"whole-person care.\"\nThe concept of whole-person care brings primary healthcare, mental health, and treatment for chronic conditions together in a virtual package that patients can access from their phones. Teladoc has the technology to use data and analytics to create a more personalized healthcare experience due to its 2020 acquisition of Livongo for $18.5 billion in cash and stock.\nA new reality?\nTeladoc was one of those ideal \"COVID stocks\" as lockdowns and avoiding face-to-face visits for fear of getting sick drove a significant increase in telehealth usage. The company saw revenue growth accelerate from around 20% before COVID to triple digits during the pandemic.\nTDOC Revenue (Quarterly YOY Growth) data by YCharts\nRevenue growth has started to decelerate, in part because of the difficult year-over-year comparisons. Investors could be worried that a post-lockdown world will see the company's revenue growth slow to pre-pandemic levels, but is this likely?\nTeladoc's Primary360 system could be the key to growth beyond the pandemic, but COVID seems to be helping the company in the near term. The omicron variant is the latest and most contagious mutation of the virus. Initial studies show that vaccinations are less effective against the omicron variant with efficacy against infection as low as 30%.\nWhile we might not experience lockdowns to the extent that we did in 2020, we still might see continued adoption of virtual services to protect vulnerable people from exposure. This could drive the near-term telehealth business and speed up adoption of virtual healthcare systems like Primary360.\nYears of growth ahead\nTeladoc may benefit from these circumstances in 2022. Still, the long-term story is the permanent shift to Primary360 if patients decide that all-in-one virtual care is better than the traditional system. Teladoc fully launched its Primary360 platform just a couple of months ago and will market it through health plans, insurers, employers, and directly to consumers.\nIn November, management held an investor event and released multiyear revenue guidance of 25% to 30% growth per year through 2024. Going to market through all healthcare channels should allow the company to grow its user base -- and then sell multiple products to those users, further compounding revenue growth.\nThe company estimates that 80% of the population could benefit from one or more of Teladoc's services, which translates to a $261 billion potential market in the United States alone, meaning the company has penetrated less than 1% given its $2 billion revenue guidance for 2021.\nDepressed valuation could mean big gains ahead\nInvestors have steadily sold off Teladoc stock since lockdowns peaked, probably on concerns that the company was a pandemic play -- and its success a momentary flash in the pan.\nTDOC PS Ratio data by YCharts\nNo doubt, the shares could still go lower in the short term as growth stocks in general have had a tough time over the past couple of months. On the other hand, virtually all of the pandemic hype seems to be priced out of the shares now with the price-to-sales (P/S) ratio down from 24 to under 8, less than its pre-pandemic valuation.\nIf the company performs to the expectations it laid out recently, investors are looking at 25% to 30% annual returns over the next several years just from organic growth of the business. Primary360's potential success might also improve sentiment toward Teladoc, which could mean an increased valuation, further driving investor returns.\nTeladoc's recent trajectory might understandably cause doubters, but I think the stock could also be one of 2022's biggest winners after being kicked to the curb in 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":788,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853782666,"gmtCreate":1634842198250,"gmtModify":1634842198360,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095866673656650","authorIdStr":"4095866673656650"},"themes":[],"htmlText":"Good sign to buy more,,, bullish","listText":"Good sign to buy more,,, bullish","text":"Good sign to buy more,,, bullish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853782666","repostId":"2177426435","repostType":2,"isVote":1,"tweetType":1,"viewCount":723,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859195823,"gmtCreate":1634664025864,"gmtModify":1634664025991,"author":{"id":"4095866673656650","authorId":"4095866673656650","name":"Ramlacs","avatar":"https://static.tigerbbs.com/6114e5ad0acd023e3e84fc15fc415255","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095866673656650","authorIdStr":"4095866673656650"},"themes":[],"htmlText":"Very good,,,more IPO’s and more choices","listText":"Very good,,,more IPO’s and more choices","text":"Very good,,,more IPO’s and more choices","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859195823","repostId":"1155284413","repostType":2,"repost":{"id":"1155284413","pubTimestamp":1633260656,"share":"https://www.laohu8.com/m/news/1155284413?lang=&edition=full","pubTime":"2021-10-03 19:30","market":"us","language":"en","title":"US IPO Weekly Recap: The IPO market can see clearly now in a 4 IPO, 2 direct listing week","url":"https://stock-news.laohu8.com/highlight/detail?id=1155284413","media":"Renaissance Capital","summary":"The IPO market remained active this past week as four IPOs raised $2.3 billion, joined by two direct listings. SPAC activity kept steady with nine blank check IPOs. New filers continue to pour into the IPO pipeline, with 17 IPOs and 10 SPACs submitting initial filings.NYSE direct listingWarby Parker opened for trading at $54  for an implied market value of $6.6 billion market cap. Warby Parker sells prescription glasses starting at $95 per pair through both its online store and in over 145 physi","content":"<p>The IPO market remained active this past week as four IPOs raised $2.3 billion, joined by two direct listings. SPAC activity kept steady with nine blank check IPOs. New filers continue to pour into the IPO pipeline, with 17 IPOs and 10 SPACs submitting initial filings.</p>\n<p>NYSE direct listing<b>Warby Parker</b>(WRBY) opened for trading at $54 (+35% vs. reference price) for an implied market value of $6.6 billion market cap. Warby Parker sells prescription glasses starting at $95 per pair through both its online store and in over 145 physical locations. Despite operating in an increasingly competitive space, this eyeglasses retailer has a track record of steady growth and a sticky customer base. Warby Parker finished up 34%.</p>\n<p>Nasdaq direct listing<b>Amplitude</b>(AMPL) opened for trading at $50 (+43% vs. reference price) for an implied market value of $6.6 billion market cap. Amplitude provides a customer behavior analytics for over 1,200 customers to improve and optimize digital products and businesses. Growing but unprofitable, this digital optimization company has a large market opportunity. Amplitude finished up 56%.</p>\n<p>Hair care brand<b>Olaplex Holdings</b>(OLPX) upsized and priced above the upwardly revised range to raise $1.5 billion at a $14.5 billion market cap. Backed by Advent, this company is a leading brand of prestige hair health products containing a patented repair ingredient. Olaplex operates in a crowded market, but has demonstrated explosive growth and robust profitability. Olaplex finished up 9%.</p>\n<p>Tech services provider<b>TDCX</b>(TDCX) upsized and priced at the high end to raise $348 million at a $2.6 billion market cap. This Singapore-based company provides digital customer experience solutions globally in more than 20 languages. Despite operating in competitive markets, the company has delivered solid growth, and it has a multibillion-dollar opportunity. TDCX finished up 6%.</p>\n<p>Drug discovery platform<b>Exscientia</b>(EXAI) upsized and priced at the high end to raise $305 million at a $2.7 billion market cap. This AI-driven biotech develops and licenses small molecule therapies, as well as its drug discovery platform. Exscientia has a large pipeline and collaborations with global pharmaceutical companies, though it is early stage and faces significant competition. Exscientia finished up 23%.</p>\n<p>Restaurant chain<b>First Watch Restaurant Group</b>(FWRG) priced within the range to raise $170 million at a $1.1 billion market cap. Only serving breakfast, brunch, and lunch, this restaurant chain owns and franchises over 420 locations across the US. Despite continued labor and food shortages, First Watch Restaurant Group has had a strong recovery from the pandemic with double digit same-restaurant sales. First Watch finished up 23%.</p>\n<p>Nine blank check companies raised $1.9 billion this past week led by industrial technology-focused<b>Hennessy Capital Investment VI</b>(HCVIU), which raised $300 million.</p>\n<p><img src=\"https://static.tigerbbs.com/a681846856e2b1a43f86b6fa0259bfa5\" tg-width=\"1252\" tg-height=\"1158\" referrerpolicy=\"no-referrer\">17 IPOs submitted initial filings this past week. EV developer<b>Rivian Automotive</b>(RIVN) filed for an estimated $6 billion IPO. Revenue cycle management platform<b>Ensemble Health Partners</b>(ENSB) filed for an estimated $500 million IPO. Restaurant chain<b>Portillo’s</b>(PTLO) filed for an estimated $400 million IPO. Specialty chemicals producer<b>Hexion Holdings</b>&nbsp;(HXN) filed for an estimated $250 million IPO. Girl’s fashion retailer<b>Claire’s</b>(CLRS), inflammatory disease biotech<b>Ventyx Biosciences</b>(VTYX), energy storage provider<b>Fluence Energy</b>(FLNC), medical device maker<b>Minerva Surgical</b>(UTRS), investment solutions provider<b>P10</b>(PX), coconut water brand<b>The Vita Coco Company</b>(COCO), aesthetic medical device provider<b>Candela Medical</b>(CDLA), enterprise cloud data management platform<b>Informatica</b>(INFA), Chinese drug in-licensor<b>LianBio</b>(LIAN), and solid tumor biotech<b>Xilio Therapeutics</b>(XLO) all filed to raise $100 million. Winery<b>Winc</b>(BEV) and technology firm<b>Arteris</b>(AIP) both filed to raise $75 million. Micro-cap biotech<b>Hillstream BioPharma</b>(HILS) filed to raise $17 million.</p>\n<p>Ten SPACs submitted initial filings, led by transportation-focused<b>Pegasus Digital Mobility Acquisition</b>(PGSS.U), which filed to raise $200 million.</p>\n<p><img src=\"https://static.tigerbbs.com/05f42f61a7ec409537e3b79a1b8f9952\" tg-width=\"946\" tg-height=\"1490\" referrerpolicy=\"no-referrer\"><b>IPO Market Snapshot</b></p>\n<p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 9/16/2021, the Renaissance IPO Index was up 7.8% year-to-date, while the S&amp;P 500 was up 19.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 14.8% year-to-date, while the ACWX was up 9.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Smoore International and EQT Partners.</p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The IPO market can see clearly now in a 4 IPO, 2 direct listing week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The IPO market can see clearly now in a 4 IPO, 2 direct listing week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-03 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/86744/US-IPO-Weekly-Recap-The-IPO-market-can-see-clearly-now-in-a-4-IPO-2-direct-><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market remained active this past week as four IPOs raised $2.3 billion, joined by two direct listings. SPAC activity kept steady with nine blank check IPOs. New filers continue to pour into ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86744/US-IPO-Weekly-Recap-The-IPO-market-can-see-clearly-now-in-a-4-IPO-2-direct-\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMPL":"AmplitudeE, Inc.","WRBY":"Warby Parker Inc.","TDCX":"TDCX Inc.","OLPX":"Olaplex Holdings, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86744/US-IPO-Weekly-Recap-The-IPO-market-can-see-clearly-now-in-a-4-IPO-2-direct-","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155284413","content_text":"The IPO market remained active this past week as four IPOs raised $2.3 billion, joined by two direct listings. SPAC activity kept steady with nine blank check IPOs. New filers continue to pour into the IPO pipeline, with 17 IPOs and 10 SPACs submitting initial filings.\nNYSE direct listingWarby Parker(WRBY) opened for trading at $54 (+35% vs. reference price) for an implied market value of $6.6 billion market cap. Warby Parker sells prescription glasses starting at $95 per pair through both its online store and in over 145 physical locations. Despite operating in an increasingly competitive space, this eyeglasses retailer has a track record of steady growth and a sticky customer base. Warby Parker finished up 34%.\nNasdaq direct listingAmplitude(AMPL) opened for trading at $50 (+43% vs. reference price) for an implied market value of $6.6 billion market cap. Amplitude provides a customer behavior analytics for over 1,200 customers to improve and optimize digital products and businesses. Growing but unprofitable, this digital optimization company has a large market opportunity. Amplitude finished up 56%.\nHair care brandOlaplex Holdings(OLPX) upsized and priced above the upwardly revised range to raise $1.5 billion at a $14.5 billion market cap. Backed by Advent, this company is a leading brand of prestige hair health products containing a patented repair ingredient. Olaplex operates in a crowded market, but has demonstrated explosive growth and robust profitability. Olaplex finished up 9%.\nTech services providerTDCX(TDCX) upsized and priced at the high end to raise $348 million at a $2.6 billion market cap. This Singapore-based company provides digital customer experience solutions globally in more than 20 languages. Despite operating in competitive markets, the company has delivered solid growth, and it has a multibillion-dollar opportunity. TDCX finished up 6%.\nDrug discovery platformExscientia(EXAI) upsized and priced at the high end to raise $305 million at a $2.7 billion market cap. This AI-driven biotech develops and licenses small molecule therapies, as well as its drug discovery platform. Exscientia has a large pipeline and collaborations with global pharmaceutical companies, though it is early stage and faces significant competition. Exscientia finished up 23%.\nRestaurant chainFirst Watch Restaurant Group(FWRG) priced within the range to raise $170 million at a $1.1 billion market cap. Only serving breakfast, brunch, and lunch, this restaurant chain owns and franchises over 420 locations across the US. Despite continued labor and food shortages, First Watch Restaurant Group has had a strong recovery from the pandemic with double digit same-restaurant sales. First Watch finished up 23%.\nNine blank check companies raised $1.9 billion this past week led by industrial technology-focusedHennessy Capital Investment VI(HCVIU), which raised $300 million.\n17 IPOs submitted initial filings this past week. EV developerRivian Automotive(RIVN) filed for an estimated $6 billion IPO. Revenue cycle management platformEnsemble Health Partners(ENSB) filed for an estimated $500 million IPO. Restaurant chainPortillo’s(PTLO) filed for an estimated $400 million IPO. Specialty chemicals producerHexion Holdings (HXN) filed for an estimated $250 million IPO. Girl’s fashion retailerClaire’s(CLRS), inflammatory disease biotechVentyx Biosciences(VTYX), energy storage providerFluence Energy(FLNC), medical device makerMinerva Surgical(UTRS), investment solutions providerP10(PX), coconut water brandThe Vita Coco Company(COCO), aesthetic medical device providerCandela Medical(CDLA), enterprise cloud data management platformInformatica(INFA), Chinese drug in-licensorLianBio(LIAN), and solid tumor biotechXilio Therapeutics(XLO) all filed to raise $100 million. WineryWinc(BEV) and technology firmArteris(AIP) both filed to raise $75 million. Micro-cap biotechHillstream BioPharma(HILS) filed to raise $17 million.\nTen SPACs submitted initial filings, led by transportation-focusedPegasus Digital Mobility Acquisition(PGSS.U), which filed to raise $200 million.\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 9/16/2021, the Renaissance IPO Index was up 7.8% year-to-date, while the S&P 500 was up 19.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Palantir Technologies (PLTR). The Renaissance International IPO Index was down 14.8% year-to-date, while the ACWX was up 9.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Smoore International and EQT Partners.","news_type":1},"isVote":1,"tweetType":1,"viewCount":797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}